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This paper focuses on European small-medium ‘serial innovators’ at the beginning of the 
1990s and provides an empirical basis to answer the following questions: who are the upstream 
specialized small-medium technology producers? How are they distributed across countries? Are 
there technologies in which they show a relative advantage? By focusing on firms’ history, 
activities, and the description of events obtained by different data sources, we also investigates if 
technology based SMEs choose to implement a strategy based on the commercialisation of their 
technologies or if they invest in the complementary assets of production, marketing and 
distribution becoming micro-chandlerian firms. Through this analysis we are able to propose a 
taxonomy of technology based SMEs’ strategies in the market for technology, in the market for 
embedded technologies and in the market for products. 
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The growth of technology-based firms in Europe is increasingly becoming a crucial issue for 
the European competitiveness. The European report on SMEs (Eurostat, 2002) points out the 
crucial role of small and new technology based firms for the conversion of scientific and 
technological innovation in new products and processes. Recent theoretical contributions suggest 
that the development of markets for technologies may sustain the entry and growth of small 
technology-based firms and there is also evidence that the  markets for technology are more 
underdeveloped in Europe as compared to the US. (Arora, Fosfuri and Gambardella, 2001). They 
report that in Europe there are less bio-tech start-ups because of the different financial 
institutional environment supporting the creation of new firms, while in semiconductors large 
European companies like Philips, Siemens, STM, Bull, Thomson CSF seem to be less active in 
terms of licensing and cross-licensing agreements with respect to their US rivals. 
Several works have pointed out the recent intensification of trade of technologies and the 
increasing extent of division of innovative labour among firms. There are several explanations 
for the emergence of markets for technologies. Among them, the internalisation of the benefits 
from specialization and internal production of technologies (in the view of Stigler, 1951); the 
increasing technological complexity of products forces also large diversified firms to access 
some technologies in the market through licensing, alliances, joint v entures or mergers and 
acquisitions. 
The emergence of markets for technologies implies that there are firms buying and selling 
technologies. Recent literature has emphasised the role of large firms both as buyers and sellers 
of technologies, as well as internal users of their technologies especially in the chemical and 
pharmaceutical sectors (Cesaroni, 2003), the electronics and semiconductors (Grindley and 
Teece, 1997). 
However, the literature has much less emphasised the role and the strategies played by small 
and medium firms in the market for technologies, in particular as suppliers of technologies 
through licensing, as developers and producers of intermediate technology inputs or as 
developers of technologies integrated into final products. 
Recent empirical evidence for the US suggests that in sectors like the semiconductor, the 
biotechnology, the medical electronics (Rosenberg, 2000; Arora et al., 2001) the small firms 
managed to grow by focusing on the technology development activities and by establishing 
supply or cooperative agreements with large firms. These are also the sectors in which licensing   3  
 
strategies of US firms are more diffused (Anand and Khanna, 2000), although the motives for 
licensing may be different for large and small firms.  
In a recent contribution, Hicks and Buchanan (2003) have also argued that small “serial 
innovators”, that is small US companies with 15 or more USPTO patents in 1996-2000, are often 
suppliers in the markets for technology. Other recent works explored the determinants of 
commercialisation strategies of a sample of start-up innovators by distinguishing firms that 
adopted a cooperation strategy in the market for “ideas” (based on licensing, acquisitions, 
alliances) and firms adopting other strategies, considered by default as competing in the product 
market (Gans et al., 2002; Gans and Stern, 2003).  
This paper contributes to this issue by investigating the characteristics and the patterns of 
growth of technology-based SMEs who serially innovate in Europe. In particular it provides an 
empirical basis to answer the following questions: how the serial innovators are distributed 
across countries, sectors and size? how important are the technologies of the large and small 
serial innovators? What are the strategies of small serial innovators?  
In particular the paper wants to add novel empirical evidence on one area that is still largely 
unexplored, that is the strategies and the patterns of growth of the upstream specialized 
technology producers. In particular we aim to understand if small technology-based firms can 
grow by implementing business strategies focused on the development and commercialisation of 
their core technologies, i.e. by operating in the markets for technology, or if they also need to 
move downstream by investing in manufacturing and distribution assets and capabilities to 
compete in the markets for products and services and appropriate the returns from their 
innovations (Teece, 1986).  
The empirical analysis developed in this paper aims to uncover the characteristics and the 
technological strategies of the serial innovators in Europe.  
First, we use the European Patent Office (EPO) database to select our sample of serial 
innovators in Europe, characterised as European firms with at least five EPO patents for which 
they applied between 1990-1995. We use the REFI database on patent citations and 
complementary sources like Who Owns Whom and Dun & Bradstreet Europe to collect 
company level data on sectors, number of employees, parent and subsidiaries. The analysis of 
these data shows the country and sectoral distribution and the relative importance of technologies 
of serial innovators by size classes (small, medium and large). 
Second, we use several information sources (Promt, ASAP, Hoovers, SDC, EPO databases 
and the companies’ web sites) in order to empirically assess the relative importance of the 
strategy adopted by the small firms, that is if they simply sell their technologies or if they invest   4  
 
in complementary assets to become a micro-chandlerian firm. From the analysis of our sample of 
small technology based firms we are able to propose a taxonomy of three main groups of 
competitive strategies in the “market for technologies”, in the “market for embedded 
technologies” or in the “market for products”. We also build several firms’ case studies that aim 
to support the validity of the classification of different types of technological strategies. 
The paper will be organised as follows. Section 2 will present the goal of the paper, the 
background literature and the development of the main argument of the paper. Section 3 will 
describe the data and the sample construction procedure. Section 4 will present some descriptive 
statistics on the sample of European Serial Innovators and some analysis mainly focused on 
patenting activity of these firms. Section 5 will propose a classification of the company strategies 
based on a deep investigation of the sample of small serial innovators. A concluding section will 
present some avenues for further research. 
 
2.  Technology-based firms and markets for technology 
Technology management and patenting of large and small firms 
Several recent works pointed out that large and small firms are changing the way in which 
they manage technology. Kortum and Lerner (1999) analyse the recent surge in US patenting 
(from 40-80.000 patents per year in the 1980s to more than 120.000 patents in 1995), and point 
out that small and new firms are exploiting the patent system more aggressively and that their 
relative share of patents is substantially increased with respect to large firms. Both large and 
small firms have shown positive rates of growth of their patenting activities but small and new 
firms have grown more. A careful analysis of the possible explanations for the upsurge of US 
patents, based on institutional changes of the patents system and on the increase of opportunities 
for technological innovation suggests in fact that these two factors cannot account for the general 
growth of patenting activities. By exclusion they suggest that the change in the management of 
innovation strategies of large and small firms can represent one of the main relevant factors.  
Their hypothesis is also supported by other works on firms’ patent activities, which show that 
firms appropriate the return from their innovation with different means. In particular in the last 
decade there has been a change in the reasons for patenting by firms in different sectors. In most 
cases patents are considered less effective for appropriating the returns from product and process 
innovation with respect to means like secrecy, lead time, investments in complementary assets   5  
 
(Levin et al., 1987; Cohen et al. 2000)
2. Among the changing reasons for patenting licensing 
emerges as important in the pharmaceutical sector, while prevention from copying, protecting 
against infringement suits and cross-licensing has become very important in the semiconductor 
and electronics industries (also confirmed by the studies of Grindley and Teece, 1997; Anand 
and Khanna, 2001). 
Hall and Ziedonis (2001) have developed a careful analysis of the different determinants of 
patenting for large firms with manufacturing facilities and design firms in the semiconductor 
industry. They aim to understand why the number of patents and the propensity to patent with 
respect to R&D has strongly increased from 1979 to 1995 although patents are considered the 
least effective way for appropriating the returns from innovation in the Cohen et al. (2000) 
survey. The results of a qualitative and quantitative analysis reveal the different patenting 
behaviour of the two types of firms. Large firms patent to protect against possible infringements 
suits and to build a patent portfolio to be used in cross-licensing negotiations with large rivals. 
Design firms with no manufacturing facilities patent to appropriate the returns from innovation 
in technology niches and to trade technologies with the owners of other complementary assets (in 
particular with foundries providing the manufacturing facilities). 
 
Large and small firms in the markets for technology 
The change in the management of innovation hypothesis and the different behaviour of large 
and small firms is in line with the theoretical and empirical work of Arora, Fosfuri and 
Gambardella (2001) on the emergence and increasing use of the markets for technologies. They 
point out that trade in technology is more common than in the past, and that together with the 
intensification of patenting activities there has been an increase in the licensing revenues. They 
provide two different explanations for the presence of large and small firms in the market for 
technologies. 
Large firms may obtain revenues from licensing their technologies when their share in the 
product market is small or in markets in which they do not wish to produce, like in geographical 
distant markets or when there is high competition in downstream markets. In these ways 
companies may increase their rents from R&D activities through license fees. Large firms may 
also exchange their technologies within R&D alliances or cross licensing agreements to acquire 
technology which is owned by other companies but it is necessary for internally producing multi-
technology products.  
                                                 
2 Although Cohen et al. (2000) do not observe the timing of the firms decisions, they suggest that firms first 
maintain the secret to have the time to invest in complementary assets, accumulate knowledge through learning 
and lead time, then they patent their technologies to avoid the entry of competitors.    6  
 
In their core markets, large firms may instead protect their intellectual property, invest in the 
complementary assets for production and distribution and compete in the market for products. In 
this case it is less likely that firms sell their technologies, thus providing access to rival firms. For 
example licensing can not be a sensible strategy in markets that are small in size (e.g. butyl 
rubber for Exxon chemicals or wire and cable applications for Union Carbide), in which few 
firms have a strong position, because licensing tends to increase entry and reduce profit 
margins. 
In a model Arora and Fosfuri (2003) suggest that the level of competition in the market for 
products affects the incentives of firms to licence technologies in markets in which they also 
produce. They compare a revenue effect obtained through the licensing fees and a rent 
dissipation effect  deriving from the increased competition in the product market. The 
monopolist firm will have no incentives to license the technologies because the rent 
dissipation effect will be maximum. If there are other competitors in the product market, the 
rent dissipation effect will be shared across all competitors thus increasing the incentive to 
license. On the other hand, firms missing the production and commercialisation capabilities 
and with no share in the product market have the maximum incentive to license their 
technologies.  
A general message that can be drawn is that large firms commercialise their  non core 
technologies while protect their core technologies, except for the cases in which they need to 
gain access to external technologies through cross-licensing (or in which the revenue effect is 
larger than the rent dissipation effect)
3.  
For small and new firms focused on the technological development more than on the 
production and commercialisation activities, licensing may instead allow to appropriate the 
returns from innovation. Markets for technologies may be critical because the cost to access to 
complementary assets may be excessive. Small firms operating in the market for technologies 
may outsource production and develop commercialisation assets either internally or through 
alliances with other companies. However, if they invested in costly complementary assets in 
production and distribution, they would need to continuously invest in new technologies to feed 
those assets.  
Arora et al. (2001) have shown some examples of small US companies missing the 
capabilities for efficiently investing in manufacturing but that manage to grow by outsourcing 
the manufacturing to large established firms. This strategy is quite common for the US 
semiconductor companies designing ASICs to be produced in the large foundries, as also 
                                                 
3 The distinction between core and non-core must be referred to the fact that firms enter or not in the product 
market (also geographic).   7  
 
reported in Hall and Ziedonis (2001). A revealing case is the company Cambridge Digital 
Technologies, whose founders where originally university researchers, that started to invest in 
manufacturing and avoided the failure only when they changed strategy by focusing on the 
licensing of their technologies and on R&D agreements with large companies possessing the 
assets and capabilities for manufacturing and commercialising the products. 
Another interesting example is the US medical device industry, which is composed of more 
than 10.000 firms (Rosenberg, 2000). Most firms are very small and are concentrated on the 
early stage of development, while there are several large firms that invest in later stages of the 
development process and produce the final product. Large firms often fund research conducted 
in small firms also with the intention to acquire the small firms developing promising 
technologies. Small firms seek to be acquired by large firms, to sell their technologies or to start 
joint research and development, manufacturing or marketing. Only in a very few cases new small 
firms became successful in the product market. 
Recently Hicks and Buchanan (2003) have argued that small “serial innovators”, that is 
“small firms with a sustained, public record of successful technical advance”, are often suppliers 
in the markets for technology. They suggest that serial innovators have formal R&D structures, 
outsource R&D for large firms or conduct R&D with the support of large firms, they focus on 
core technologies (instead of core products) in particular where markets are well developed. 
They compare some characteristics and the patenting performances of small US serial innovators 
with that of large firms, and find that small serial innovators produce technology of higher 
quality, more broadly based and more closely linked to scientific research. They also observe 
that these firms are younger than large firms.  
A direct evidence on the participation of small firms in the markets for technology is 
represented by the data on co-assigned patents, that is patents jointly owned by two or more 
organizations. According to Hagedoorn (2002) co-assigned patents are the result of small scale 
joint R&D that may have produced only a few patents (one or two). In this case small firms 
jointly develop and exchange technology, but also manage together the protection of their 
inventions since in small-scale projects it is difficult to assign separately the intellectual property. 
Hicks and Buchanan (2003) find that 3.2% of small firm patents are co-assigned, compared to 
1.7% of large firm patents. The larger share of co-assigned patents by small firms suggests that it 
is more likely that they are involved in joint research and development activities and supports the 
idea that they work in the markets for technology. 
In a similar vein Gans et al. (2002) and Gans and Stern (2003) explored the determinants of 
the commercialisation strategies of a sample of US start-up innovators by distinguishing firms   8  
 
that adopted a cooperation strategy in the market for “ideas” (based on licensing, acquisitions, 
alliances) and firms adopting other strategies, considered by default as competing in the product 
market (Gans et al., 2002; Gans and Stern, 2003). They find that determinants of the cooperation 
strategy are the strength of intellectual property protection, lower transaction costs and the 
existence of high sunk costs of entry into the product market.  
 
Technology suppliers or micro-chandlerian firms? 
Our work builds on this literature and aims to contribute in two directions.  
First, it aims to identify the strategies of small technology-based firms as producers, sellers or 
users of technologies. Technology-based firms may develop technologies for different purposes: 
(i) for internal use in the manufacturing of products; (ii) for selling technologies through 
licensing or other agreements or for selling intermediate technology inputs requiring some 
manufacturing activity; (iii) for creating absorptive capacity of external knowledge or for other 
possible reasons (for example new technologies may be the unexpected results of research or 
manufacturing activity that are not finally used internally or externally). At the same time firms 
may buy technologies for internal use. The literature has suggested that in many cases large firms 
both buy and sell technologies, and use the technologies for the internal manufacturing of final 
products.  
For small firms the evidence is very limited and our idea is that small technology-based firms 
specialize either in the development and commercialisation of technologies or in the 
development of technologies devoted to production of products, especially in market niches. We 
aim to understand if small firms are specialised or if they implement broad strategies similarly to 
large firms. We build a taxonomy of small firms strategies in the market for technology, in the 
market for embedded technologies and in the market for products and study the position of firms 
within this taxonomy. In particular we find out who is active in the market for technology, if 
small firms focus exclusively on the supply of technologies or if this strategy is associated also to 
the supply of products, or if small firms need to move downstream b y investing in the 
complementary assets of production, marketing and distribution becoming micro-chandlerian 
firms (Chandler, 1990). The more general purpose is that of identifying viable and successful 
technology strategies for the growth of small firms. 
Second, it focuses on the European small and medium serial innovators, for which the 
empirical evidence is rather limited if compared with the US case, and develops a systematic 
empirical analysis of the strategies of technology-based firms in the market for technologies and 
in the market or products. We believe that this is an important contribution since the empirical   9  
 
evidence on this issue is very limited and partial. The evidence on markets for technologies is 
mainly based on the existence of technology trade and licensing at the sectoral level or on case 
studies at the sector or firm level. However, in most cases it calls attention to the occurrence of 
supply of technologies, mainly through licensing, without controlling for the importance of 
licensing within the overall firm strategies.  
Moreover, we analyse the country and sectoral distribution of firms in different size classes 
and the relative specialization and importance of the technologies of small and large serial 
innovators.  
 
3.  Data and Methods of Analysis 
The empirical analysis of this paper is carried out on a sample of technology-based firms in 
Europe. In order to assess the goals of our analysis, we choose to focus on firms with a sustained 
amount of patent applications in 1990-1995, similarly to Hicks and Buchanan (2003). Our 
sample was then built in several steps by using different sources of data. First, we used the EPO 
database in order to select all European firms that applied for at least 5 patents in 1990-1995, 
thus identifying the sample of European serial innovators. We decided to focus on serial 
innovators for screening a sample of firms that are very likely to be technology-based, although 
some technology based firms may be present among applicants with less than 5 patents
4. The 
choice of the period has been driven by the need of having a subsequent period for observing the 
strategies of the firms. 
At this stage, we could select 3.291 different European companies
5, which account for 34% of 
the total amount of EPO patents in this period. For the remaining 66%, we are able to identify 
29% of patents from the US and Japanese most patenting companies
6 at EPO, 18% of patent 
from other US and Japanese applicants and just 1.03 % of patents from European public research 
institutions, universities and individual inventors with more than 5 patents applications each. The 
lasting 18.03 % of patents belong to other European applicants with less than five patents and 
other non EU, US and Japanese applicants. Second, for each of the 3.291 European companies 
we searched in the D&B Europe publication (1994) data on the eventual affiliation to a parent 
company, the number of employees, sales and the sector of activity (up to five SIC codes), 
                                                 
4 It is also for this reason that we decide to select firms with at least 5 patents instead of 15 like in the work of 
Hicks and Buchanan (2003), in order to select a large sample of technology based firms. 
5 We consider here companies in all the European countries for which data are available from the publication 
D&B 1994: France, Italy, Switzerland, Belgium, Luxemburg, Austria, Germany, Spain, Great Britain, Ireland, 
Netherlands, Denmark, Norway, Sweden, Finland. 
6 We identified this percentage from the preliminary phase in which we checked the names of all the companies 
with more than 100 patents.    10  
 
collecting data for 1796 of them. For the firms that we could not find in the source D&B, we also 
checked on the source WOW 1993 whether they were subsidiaries of other firms in the period 
under observation
7. After the association of subsidiaries to their parents we had a sample of 2644 
firms and we ended up with a sample of 1294 non missing serial innovators.  
This sample represents 85% of the total amount of EPO patents from European serial 
innovators in the period 1990-1995. 
In order to check for eventual biases due to the problem of missing data from the source D&B 
1994, we run a missing analysis on a random sample of these companies. We selected 150 
companies among the D&B missing serial innovators and checked for information on sales and 
employees, industrial sector, parent company, if any, and year of foundation
8. We did not find 
any strong empirical regularity in terms of industrial sector. It is not very easy to say if any 
regularity exists about the size of these firms. The fact that they were not found in the source 
D&B could suggest that they tend to be smaller in size. Moreover, the missing firms tend to be 
absent from the upper part of the distribution of firms per number of EPO patents. Nevertheless, 
most of these firms could be found on the web and, for the ones for which we could find 
information on the employees
9, we did not find a strong bias in a specific size class. If we can 
exclude that these firms are in the very upper tail of the size distribution, we cannot really say in 
which size class they are more likely to be. Furthermore, some firms are missing in the source 
D&B 1994 because they changed name after that year, for example after a merger
10. While we 
could control for this kind of missing data for well-known European firms, some other 
companies are clearly more difficult to detect. 
The empirical analysis carried out in this paper focuses on the sample of 1294 companies that 
we could identify in the source D&B 1994 and try to delineate their characteristics in terms of 
size, sectors, patenting activity, technologies, and their strategies. In particular we highlight the 
different characteristics of small-medium serial innovators with respect to the large ones. In so 
doing, we first produce an accurate analysis of the patenting activity of our sample of European 
serial innovators considering the sub-samples of firms with less than 250, 250-500 and more than 
500 employees (see Section 4). We also use the REFI database on patent citations updated to 
                                                 
7 17% of the companies that were missing in the source D&B 1994 resulted as subsidiaries of other companies in 
the source WOW 1993. 
8 We mainly checked on the company web pages the companies.  
9 Only for 30 of these firms we could not find any information on the web. For the others, in most of the cases 
we could not find systematic information on all the variables of interest. For almost all of them we can identify 
the industrial sector. 
10 On the Epo database we can often find firms with the name they started to have after a merger, even if this 
happened after the year the patent was applied.    11  
 
2003 to study the relative importance of patents of large and small firms in different 
technological classes. 
Second, we focus on the sub-sample of 114 small serial innovators and develop a taxonomy 
of their technological and business strategies. 
This classification is based on an analysis of a series of events, identified through several 
sources of data and information at the company level. From the SDC database we extract 
information about the acquisitions (firms or parts as targets or acquirors) and joint ventures, joint 
research and development, joint production, joint marketing, supply or licensing agreements. We 
also use the PROMT database, including information about product development and 
introduction, patents and copyrights, plant divestitures, alliances, partnerships, and the ASAP 
database, collecting press articles searchable for company names from 1983 onwards. The 
collection of information is complemented by the analysis of the companies’ web sites, 
especially for their history. 
The analysis of firms’ strategies is also carried out on a smaller sample of European and US 
serial innovators in the period 1996-2001 in order to provide an initial comparison between the 
strategies adopted in the first half and in the second half of the 1990’s and between European and 
US serial innovators. 
 
4.  Who are the Technology-based SMEs in Europe?  
4.1 Distribution by Country 
A preliminary analysis of the data provides a description of our sample of serial innovators in 
Europe by country  (Table  1). 77.67% of European serial innovators in our sample are 
concentrated in Germany, Italy, Great Britain and France (43.04%, 11.21%, 12.52% and 10.90% 
respectively) while the patents distribution across countries shows that Germany, France and the 
Netherlands account for the vast majority of patents by serial innovators (70% of the total and 
41.96%, 16.90% and 10.80% respectively, against 8.47% for Great Britain and just 5.39% for 
Italy). This clearly reflects the different composition of the firm size distributions across 
countries. While in the Netherlands a high percentage of patents are owned by relatively few 
large companies (11.03%)  – with a very high average number of patents per large serial 
innovator –, Great Britain and Italy account for a high percentage of patents by small-medium 
serial innovators (36.51% and 23.48% respectively) with a relative lower contribution from large 
firms, particularly for Italy. In Great Britain the high contribution in the patenting activity 
emerging from small-medium serial innovators relies almost exclusively on one very innovative 
actor – the British Technology Group -, which also has a high average number of patents per   12  
 
firm. This company accounts for 73% of the patents from small serial innovators in Great 
Britain
11. Italy is, indeed, characterised by a lower average number of patents of small-medium 
technology based firms.  
These findings are also in line with the aggregate statistics for R&D expenditures and for the 
propensity to patent in the different European countries
12.  
[TABLE 1 ABOUT HERE] 
4.2 Distribution by sector of activity 
The classification of serial innovators by industrial sectors (SIC 2-digit) shows that the largest 
share of companies is concentrated in the industrial machinery and equipment sectors (SIC 35), 
electronics and other electrical equipment sectors (SIC 36) and in the chemical and allied 
products sectors (SIC 28) (Table 2). This can be observed both for the small-medium and for the 
large firms. 49% of the patents in the sample are applied by firms in SIC 36 and 28 sectors, 
where the average number of patent per firm is very high for the large ones.  
This distribution is in line with previous contributions which highlight two main patterns: 
first, serial innovators are concentrated in industries in which technical innovation and patent 
protection are important (Hicks and Buchanan, 2003); second, the bulk of licensing activity is 
concentrated in the SIC 35, 36 and 28 industries (Anand and Khanna, 2000).  
A substantial number of firms in all size classes is also active in fabricated metal products 
(ranked 4
th in Table 2) while the transportation sector is mainly populated by large firms. are 
relatively more active in the instrument sector (SIC 38). 
If we observe the average number of patents by serial innovators the rank is quite different. 
Large firms have a very large share of patents in the communication, oil, petroleum, chemical, 
electronics, metal mining and transportation sectors, while the average number of patents is 
evidently smaller in the industrial machinery, metal products, instruments and rubber sectors
13. It 
is worth noting that the metal and machinery sectors are characterised by a lower propensity to 
patent and a lower perceived effectiveness of patents as a mean for appropriating the returns 
from innovation (Cohen et al., 2000). Interestingly, as it will be shown in the following tables in 
which small firms are more specialised.  
                                                 
11 We report in each table also the values obtained without considering this company. 
12 We used the Third European Report on Science and Technology Indicators (2003) and the European Report, 
Fact and Figures (1990-2000) to check for the R&D intensity (Gross domestic expenditure on R&D as a 
percentage of GDP) and for the average number of patents per millions of inhabitants (propensity to patent) in 
the different European countries. We then standardise patents from serial innovators with population in the 
different countries and we compare them with the propensity to patent of the country.  
13 The standard deviation in the average number of patents per serial innovators is, as expected, very high in 
these sectors. In SIC 35, where the average number of patents per large serial innovators is relatively low, the 
standard deviation is 137.334. In SIC 36 and SIC 28 the standard deviation is respectively 765.138 and 720.256. 
This is due to the presence of very few firms with a very large number of patents.      13  
 
[TABLE 2 ABOUT HERE] 
The cross country-sector distribution of companies (not shown in the tables) reveals that the 
countries with the largest number of companies are also mainly present in the more crowded 
sectors. However,  when we restrict our analysis to small-medium firms in the sample,  the 
German firms represent a high percentage of the total firms in  sectors like  fabricated metal 
products, SIC 34, and industrial machinery and equipment, SIC 35, (43% and 41% respectively), 
while in the chemicals and allied products the Italian firms account for the highest percentage 
(50% with respect to the 15% of German firms).  
 
4.3 The Technological Specialization of small-medium European serial innovators 
The classification of patents by technological class for groups of firms in different class size 
shows that the distribution of large, small and medium firms is not uniform across technologies 
(Table  3)
14.  All firms own a high share of patents in organic fine chemistry, analysis, 
measurement & control, electrical devices, electrical engineering and electrical energy. Firms 
with less than 250 employees and with 251-500 employees are relatively more present in civil 
engineering, building, mining,  medical, pharmaceutical and mechanical sectors. Large firms 
have a relatively higher share of patents in the transportation and communication sectors. In 
some sectors like chemical engineering and medical instruments only medium firms show a 
relatively higher presence. 
To check for the relative technological specialization of groups of firms in different size 
classes we computed the RTA (Revealed technological advantage) indicator as the percentage of 
patents in the size class relative to the percentage of patents from each firm in the period 1990-
1995
15. We then considered the adjusted RTA as adjRTAij = (RTAij –1)/( RTAij +1) in order to 
constrain it in the interval (-1,1). 
Table 3 reveals that firms are relatively specialised in technologies in which their presence is 
also relatively large. Moreover, it is interesting to note that the technological classes in which 
small firms are specialised are often different from medium but especially from large firms. Even 
when firms in different size classes show a positive RTA, their level of specialization is quite 
different. This different pattern of technological specialization may suggest a division of 
                                                 
14 We use the technology-oriented classification system elaborated jointly by the German Fraunhofer Institute of 
Systems and Innovation Research (ISI), the French patent office (INIPI) and the Observatoire des Science and 
des Techniques (OST). It distinguishes 30 different fields of technology and five higher-level technology areas 
based on the International Patent Classification (IPC). For a direct comparison between ISI-INIPI-OST 
technological classes and EPO IPC classes see for example “Statistical Analysis on the Distance Between Fields 
of Technology”, Hinze, S., Reiss, T. and U. Schmoch, 1997. 
15 The RTA index is calculated as follows: RTAij = (Pij/SjPij)/(SiPij/SijPij), where Pij is the number of patents 
owned by firm i in the technological class j. The index measures the specialisation of firm i in the technology j 
weighted by the specialisation of all firms in that technological class.   14  
 
inventive labour across these groups of firms. In particular, most of the technologies in which 
SMEs are more specialised are relative to chemical and engineering activities, mechanical 
elements and tools, materials and processes, that are technologies commonly supplied to larger 
firms. 
 
[TABLE 3 ABOUT HERE] 
We report in Table 4 a measure of the value of patents owned by firms of different size in 
each technological class. For each technological class j we computed the citation intensity 
(average number of citations per patent) for the firms in each size class relative to the citations 
intensity for all the firms patenting in the whole period 1990-1995 in the same class j. The index 
has been normalised like the RTA. 
SMEs have in some technological classes higher citation intensity compared to large firms. 
This occurs in several classes in which SMEs are more specialised but also in some technologies 
like the transportation in which large firms are more specialised. Potentially these very good 
patents may be protected and incorporated in products sold to the final market or may be 
supplied to large firms. Patents of large and medium firms appear more valuable in different 
classes with respect to small firms (audiovisual technologies and telecommunication for medium 
firms and chemical, pharmaceuticals and biotechnology for large firms). 
[TABLE 4 ABOUT HERE] 
An interesting comparison can be done with the situation in the US (Hicks and Buchanan, 
2003), in which most of the patents from serial innovators with less than 500 employees in 1996 
– 2000 are in pharmaceutical technologies and in biotechnologies and medical instruments and 
equipment
16. Moreover, as emphasised in Rosenberg (2002), many new science based firms 
spun-off from universities have been created in the medical and biotechnologies. In Europe we 
also observe a relatively large presence of small and medium serial innovators in these 
technologies although the relative quality is not very high. 
The empirical analysis in this section has shown some interesting differences in the sectoral 
and technological distribution of firms in different size classes, and also dissimilarities in their 
technological specialization and importance of technologies.  It seems to emerge a pattern of 
division of technological labour among large firms and small serial innovators. In particular 
SMEs appear to be relatively more specialised in supplier sectors of technologies. These patterns 
                                                 
16 As part of this analysis, we plan to observe the patenting activity of the complete set of small serial innovators 
between 1990 and 1995 in the subsequent period 1996-2001. This will be done together with a control analysis 
on serial innovators selected in 1996-2001, that will allow us to better compare the share of firms and patents in 
different sectors in EU and US.      15  
 
however need to be further investigated through the analysis of the use of technologies at the 
firm level. Next section will be focused in particular to the analysis of the strategies of small and 
medium firms in the markets for technologies and in the markets for products. 
 
5.  A Taxonomy of SMEs’ Technological Strategies  
This section aims at uncovering the strategies of small-medium technology based firms. In 
fact, all technology-based SMEs identified in our sample invest persistently in innovation and 
patent their inventions, but they may adopt different strategies for the exploitation of their 
technological assets.  
We focus on the sample of 114 technology based SMEs, and identify a taxonomy of strategies 
in which these firms can be classified. The main idea underneath our taxonomy is that, among 
some alternatives, these firms may incorporate patented technologies into products sold in the 
final market, into tools, processes or other intermediate technology inputs supplied to the 
intermediate market or they can supply their technologies through licensing, provision of 
services or other cooperative agreements. In other cases they can do combinations of these 
activities.  
These strategies may imply different levels of investment in the complementary assets of 
production and distribution, and this may represent a crucial starting point for understanding the 
determinants of innovative SMEs’ survival and growth. Moreover, the identification of the these 
strategies will allow us to better understand to what extent small-medium technology based firms 
contribute to the division of innovative labour with large firms, by supplying their technology 
trough licensing or R&D contracts. 
Our process for defining the type of strategies has mainly been inductive. We can summarise 
it in two main phases. Having in mind the idea of distinguishing strategies of firms 
commercialising technologies rather than products, we first analysed in detail firms’ history, 
activities, products, technologies and important events like licensing, joint ventures, 
research/production/marketing agreements and similar. This analysis was mostly performed 
using databases on specialised press articles on firms’ events, namely ASAP and PROMPT, and 
companies’ web sites. The SDC database was used as an additional source of data on firms’ 
deals, mostly mergers and acquisitions and joint ventures.   
From the first appreciative analysis we selected and codified several facts and events related 
to the firms’ activities and strategies, which are the presence of manufacturing facilities, the 
launch of products, the provision of technical and engineering services, the presence of joint 
ventures or contracts/agreements in R&D, production or marketing/distribution, the presence of   16  
 
licensing in and out, the presence of foreign subsidiaries or sales facilities, the acquisition of 
assets in other firms, the acquisition target from other firms and, finally, the type of market (final 
or intermediate).  
Second, we analysed all these events and identified three main summary criteria for 
classifying companies. The first is the presence or absence of manufacturing facilities. The 
second is the market for the firms’ technologies or products that can be intermediate (i.e. the 
manufacturing sector) or final (i.e. the final user or the service sector). The third is the presence 
of events like licensing and R&D/technology contracts or agreements.   
The combination of these three variables allowed us to identify three ‘pure’ strategies, namely 
‘market for product’, ‘market for embedded technology’ and ‘market for technology’. The three 
strategies are described and explained in detail in section 5.1, together with some illustrative 
examples from our sample. In synthesis, the distinction between the strategy of market for 
technology and market for embedded technologies lies mainly in the presence or absence of 
manufacturing facilities, while the separation between market for embedded technologies and 
market for products depends mainly on the final market. The companies may also pursue mixed 
strategies, for example if they have manufacturing facilities and sell both intermediate inputs and 
products in the final market. Another interesting type of mixed strategy is detected through the 
presence of licensing by companies who also manufacture products to be sold in the final market. 
Our first qualitative analysis also allows us to assess the level of investment in the 
complementary assets according to the different strategies.  
A description of the factors defining the pure and the mixed strategies and a characterization 
of the strategies in terms of the level of investment in the complementary assets are reported in 
Table 5.  
It is useful to underline that all firms in our sample are technology-based and invest 
persistently in innovation, but they invest differently in complementary assets and adopt different 
ways of appropriating the returns and using the technology within the firm. Patents, which are 
important in all three strategies (since all firms serially patent their inventions), can be used for 
licensing, for developing embedded technologies (intermediate technology inputs) or are 
incorporated in the final product. In all these cases, our qualitative analysis show how many of 
these firms represent leaders in niche markets for products or technologies and in several cases 
they are suppliers of large firms in international markets.  
In section 5.2, we report some descriptive statistics on country, sector and technological 
distribution of firms in different types of strategy and emphasize the differences of firms in terms 
of some main characteristics like age, size, technological diversification, and value of their   17  
 
patents. In section 5.3 we present an initial comparison of the distribution of European serial 
innovators by type of strategy in 1990-1995 with the distribution for a smaller sample of 
European and US serial innovators in 1996-2001. 
 
[TABLE 5 ABOUT HERE] 
 
5.1 SMEs’ Strategies of exploitation of their technological innovation  
Market for technologies 
The first strategy is labelled “market for technologies”, and corresponds to cases of firms that 
supply technologies more than products, and their level of investments in complementary assets 
of production and distribution is quite low. In particular this strategy is adopted by firms that 
commercialise their technologies through licensing, technological contracting, joint research and 
development, provision of design and engineering services, training (and can include firms that 
are in total or in part acquired by other existing firms). This should be typical of firms developing 
technologies but that do not enter in the product market to compete with existing firms. The rents 
from the innovation come from the commercialisation of the technologies or from the money 
gained by the shareholders through the acquisitions by larger firms
17. A clear indicator of this 
type of strategy is the absence of manufacturing plants. Table 6 shows three interesting cases of 
companies operating in the market for technologies that we found in our sample. 
The typical case is represented by Cambridge Display Technologies (CDT), a company 
founded in 1992 by Cambridge University researchers, with the goal of further developing the 
light emitting polymers displays (LEPs) and ultimately commercialise their use. LEPs are a 
general-purpose technology with broad potential for application in several sectors. LEP displays 
are expected to appear in portable electronic products such as mobile phones, camcorders, digital 
cameras and personal digital assistants. In the long term, the technology could be scaled up for 
larger applications such as computer screens and televisions. The strategy of the companies has 
since the beginning been based on the commercialisation of the technology through the licensing 
of its patents. Many investors have funded the growth of the company, and in 1999 two New 
York based private equity funds acquired a majority interest, but the company remained based in 
the Cambridge University campus. CDT has been involved in several licensing agreements with 
large companies for the commercialisation of its technologies: Dow and Dupont, Delta 
                                                 
17 As suggested in some previously mentioned works (Rosenberg, 2000; AFG, 2001), it is worth noting that 
acquisition by established large firms could be the reason beyond the foundation of firms specialised in market 
for technology.    18  
 
Electronics, Luxell Technologies, MicroEmissive Displays, OSRAM Opto Semiconductors, 
Philips Electronics, and Seiko-Epson. In 2002 Cambridge Display Technology has acquired 
Opsys, an Oxford University based spin-off engaged in the intellectual property, 
commercialisation, and technology development of organic light emitting diode (OLED) display 
technologies. The aim of CDT was that of adding specialised scientists and competences related 
to the display technologies to finally enhance the attractiveness of its display technology 
portfolio to existing and prospective licensees.   
In the pharmaceutical industry, several companies develop and commercialise drugs through 
licensing. Many pharmaceutical companies also manufacture the drugs and sign licensing 
agreements giving the rights to commercialisation in other geographical markets. The company 
reported in Table 6, Biotie Therapies, has a strategy focused on the early stages of research and 
clinical development, and on licensing agreements to o ther companies at the late stage 
development and manufacturing of the drugs. NeuroSearch is another biopharmaceutical 
company focused on unmet medical needs within specific diseases. NeuroSearch has a broad 
research and development portfolio, which includes compounds in clinical development and a 
number of pre-clinical and drug discovery programs and has several cooperation agreement with 
large companies. 
A very different and peculiar case is represented by the British Technology Group, which 
could be considered “a market for technology” itself, since its mission is that of developing and 
commercialising technologies developed in several fields, of favouring the founding of 
technology-based business ventures, and also of licensing in technologies to be offered to other 
potential licensees. The Group is engaged in the process of finding, developing and 
commercialising high potential technologies from a range of life and physical sciences sectors. 
These technologies come equally from universities and companies.  
[TABLE 6 ABOUT HERE] 
 
Market for embedded technologies 
The second strategy, called “ market for embedded technologies”, includes all specialised 
technology-based suppliers that develop technologies incorporated in components, machines, 
equipments, production processes which are finally used by other companies manufacturing final 
or intermediate products. The level of investments in complementary assets is larger because 
these small technology based companies often have manufacturing facilities to produce the 
component or equipment and invest in downstream assets for the commercialisation of the 
product or for the provision of training services and post-sales assistance. Firms in this category   19  
 
may adopt heterogeneous types of strategies. On the one hand they may supply a standardised 
embedded technology that is used in several sectors and products and that is produced in series (a 
general purpose technology). On the other hand firms can provide custom products or services, 
i.e. they supply customised final solutions or design and engineering services associated to a 
production technology.  
This strategy is identified through the presence of substantial R&D activities for the 
development of the embedded technology. In some cases a brilliant invention with broad 
potential for application set the basis for the growth of a small firm. Instead of investing in the 
final product, the innovative firm tries to sell the technology to all potential users. In many cases 
agreements like joint ventures, joint production and joint marketing agreements are developed 
for manufacturing and commercialising the products based on their technologies. For example 
small technology based firms may outsource some production activities and develop marketing 
alliances for the commercialisation of their products.  
Examples of this strategy are companies developing a specialised technology embedded in a 
component or machinery that is finally used in several manufacturing processes of other 
companies (Table 7). Alten Geratebau for example has become leader in dock loading and 
equipment, and the growth has become more rapid after its acquisition by the Swedish Cardo 
Group in 1998. Sihi GmbH has a similar story, producing vacuum pumps for several types of 
vehicles and has been finally acquired by the  Sterling Fluid Holdings, a subsidiary of the 
Thyssen Bornemisza group. The Braibanti pasta processing technology, installed in many 
factories producing pasta, represents another interesting case.  
In some cases the companies also provide customised solutions based on the technology, 
specialised engineering and design services or training of personnel, like for example Nuova Roj 
Electrotex or Allgon.  
[TABLE 7 ABOUT HERE] 
Market for products 
The third strategy is labelled “market for products”, which implies that firms launch some 
products, build plants, manufacture the products for final markets and invest considerably in 
downstream complementary assets in house or through acquisitions of assets from other 
companies (in total or in part). Competition in this case occurs in the product market where also 
other incumbents can be present. In many cases small firms with innovative ideas try to enter in 
confined market niches. This strategy resembles that of the large chandlerian firms and is typical 
of firms developing technologies to be integrated in final products internally manufactured. The 
events associated to this companies are the presence of in house investments in production and   20  
 
marketing, the launch of final products, the acquisitions of companies with manufacturing 
facilities, the creation of manufacturing or sales subsidiaries (see Table 8 for some examples). 
Many small companies pursuing a strategy in the market for products base their activities on 
the internal development and manufacturing of an innovative product, whose technologies are 
not commercialised to other competitors. Companies also make some investments in 
downstream complementary assets of marketing and distribution. Some examples are the 
Cimbali coffee and expresso machine, the Durst Phototechnique products for digital print or the 
bodyguard and other patented products based on innovative materials of Meliconi.  
It is worth noting that not all firms in the market for products invest since the beginning 
considerably in production and especially in marketing and distribution. in An interesting case of 
a company that progressively increased the level of investments in downstream complementary 
assets is Disetronic Medical Systems, founded in 1984 by  two brothers Willy and Peter Michel, 
who recognise that the treatment of diabetes could be substantially improved with sophisticated 
programmable insulin pumps. One of the two founders was an executive in the pharmaceutical 
industry and expert in diabetes treatment, while the other had theoretical and practical knowledge 
in physics and engineering. However the lack of funding could not allow the commercialisation 
of the insulin pumps, which was instead possible through collaboration agreements with large 
companies. In 1985 Aventis (Hoechst) took over the marketing and distribution of the MRS 
insulin pump in several large European markets and in 1986 Disetronic develops a new product 
for Aventis. In 1988 it started to invest in assets for the direct commercialisation of its products 
abroad through the creation of a foreign sales subsidiary, bought a production plant in Germany 
and in the early 1990s it launched several new products directly in the market, while still 
developing new generations of products for Aventis. The expansion has also been conducted 
through a few acquisitions of small companies (Rondo AG, Dividella and MicroMed) and has 
been associated with a growth of the sales and of the number of employees (more than 1000 in 
1999). 
 [TABLE 8 ABOUT HERE] 
 
 Mixed strategies  
Small firms may also pursue different types of mixed strategies instead of specializing either 
in the commercialisation of technologies or final products.  
First, we identify mixed strategies in the market for embedded technologies and in the market 
for products for the companies having manufacturing facilities and producing both intermediate 
technology inputs sold to the manufacturing sector and products sold to the final market. A case   21  
 
example is represented by Askoll, which invented the synchronous pump for aquariums. Its 
technology has been widely adopted by large users of home appliances like washing machines, 
dishwashers and by producers of aquariums. The company web site reports that 50 million 
aquariums use its technology and 80 million dishwashers adopt the Askoll Inside concept. At the 
same time Askoll internally manufactures aquariums and other products for gardening 
embodying the synchronous pump (Table 9). 
Second, we use the event of licensing for discriminating firms that are in the pure “market for 
technology” strategy introduced above or instead pursuing  mixed strategies, for example 
manufacturing products or embedded technologies but also licensing some of their technologies. 
In this way we identify the small firms that participate to the division of innovative labour by 
actively operating in the market for technology either with a specialised strategy of 
commercialisation of technologies or embedded technologies, or with a mixed strategy 
characterised by the presence of licensing activities.  
Several of these cases are in the pharmaceutical industry, and are characteristics of companies 
strongly devoted to the development of drugs and molecules licensed to other pharmaceutical 
companies, but also  manufacture their own products. Mediolanum Farmaceutici based its 
strategy in the early 1990s on the licensing of some molecules, but at the same time acquired two 
French companies with manufacturing facilities. Rotta Research Laboratorium develops several 
therapeutic drugs licensed within joint agreements, but also manufactured by the Rottapharm 
group.  
 
[TABLE 9 ABOUT HERE] 
 
5.2 Some insights from our sample of small-medium European Serial Innovators  
The main finding from our classification of technology based SMEs according to their 
strategy seems to show that the presence of small firms lacking the commercialisation 
capabilities to compete in the final market and specialized in technology trading in the early 90’ 
was quite limited while the bulk of European serial innovators have to be found indeed in the 
‘embedded technology’ strategy.  
The results of the complete analysis of the sample of small and medium serial innovators are 
summarised in Tables 10-13.  
Figure  1 shows that the l argest share of firms is equally distributed in the Market for 
embedded technologies (MfET) and in the Market for products (MfP) strategies. Five firms 
adopt a pure strategy in the market for technologies (MfT) and 14 firms have a mixed strategy.   22  
 
For two f irms we could not find clear information for understanding and classifying their 
strategy
18.  
The country distribution of strategies mainly reflects the overall sample distribution, with 
some difference (Table 10). In Germany the share of MfET strategies is relatively larger than the 
MfP strategy, while in Italy this share is relatively larger for the MfP strategy, although the 
differences are quite small in terms of numbers. In the UK 3 firms out of 12 adopt a pure MfT 
strategy (CDT, CAT and BTG) and it is worth noting that these companies are closely related to 
the scientific academic environment. CDT is a Cambridge University spin-off, which also 
acquired Opsys, an Oxford University spin-off also characterised by a pure MfT strategy. BTG 
has the University among its investors and its activities and technologies are strongly science 
linked. In the mixed T-P strategy there are mainly Italian companies in the pharmaceutical sector 
(SIC 2834), who invested in manufacturing facilities only  for some drugs or for the national 
markets, but rely on licensing agreement or on cooperative agreements to sell their technologies 
in markets for which they do not possess the complementary assets of production and 
distribution.  
The distribution of firms by sector (Table 11) shows that the two largest groups of strategies - 
MfET and MfP  – are present in several sectors. However, as also indicated by the SIC 
concentration index, almost half of the firms adopting the MfET strategy are in the machinery 
sector, firms in the electrical sector have mainly a MfP strategy while the pure MfT strategies are 
in the chemical-pharmaceutical and in the business and engineering service sectors. It is also 
interesting to note that all firms with Mixed T-P strategies are in the chemical-pharmaceutical 
sector.  
Table 12 summarises some firm-level characteristics by type of strategy. Firms in the pure 
MfT are younger than firms with other strategies. The distribution of size and number of patents 
per firm is quite uniform across categories, except for the BTG group, and for the three old 
companies with mixed T-ET strategy.  
Some interesting differences can be found in terms of specialization and value of 
technologies. Firms in the MfT and in the MfET are less focused than firms in the MfP, as 
shown by the Herfindhal index calculated on patent technological classes according to the ISI – 
INIPI – OST classification at the type of strategy level and at the firm level. The average number 
of citations is larger for patents used in the MfT if we exclude the British technology group from 
the analysis. Moreover, citation intensity is greater for patents of firms in mixed strategies. 
 
                                                 
18 It is also possible that they exited the market.   23  
 
 
6.  Conclusions and further research  
This paper has developed a descriptive analysis of the characteristics of the European serial 
innovators and proposed a classification of the heterogeneous technology strategies that they can 
pursue. The analysis of large and small serial innovators suggested they focus and specialise in 
different technological classes and this may suggest a division of innovative labour among firms 
of different class size in different sectors and technologies. The accurate analysis of small serial 
innovators have provided new empirical evidence related to the different strategies of technology 
based companies, that helped us to delineate a taxonomy that goes from the market for 
technology, i.e. the technology supplier firm, to the micro-chandlerian firm competing in the 
market for products and investing both in technology and in downstream complementary assets. 
This analysis allowed to explore and identify how diffuse are these strategies across firms, the 
sectoral distribution and technological specialization and the value of patents in different classes. 
In the progress of this work we will identify if there are strategic dynamics patterns of firms 
moving across these strategies during their life or if firms stick to a main strategy, and if 
acquisitions of firms by large firms play a relevant role in the dynamic pattern of firms in the 
market for technology. Some examples of large and medium firms active in the market for 
technologies will also contribute to deepen this issue. 
Starting from this classification, we aim to investigate the evolution and the strategic patterns 
of these firms trying to assess the relations between technological strategy and the related 
performances. This analysis will allow to answer some of our initial questions on the probability 
of entry and growth of companies focused on the commercialisation of technologies as a main 
strategy of appropriation of the returns from innovation and on the easier entry in the market for 
technology suppliers, in particular in markets where the development of complementary assets is 
too costly for new and small firms.  
We also aim to understand if there are geographic patterns of distribution of firms in the 
market for technologies, if markets for technologies emerges in some areas instead of others, and 
if relations with large firms, universities, venture capital are important for the emergence and 
growth of specialised technology producers. 
In the future research we will develop a broader comparison of the characteristics of small-
medium serial innovators in Europe, with the US serial innovators as described in Hicks and 
Buchanan (2003). Our future analysis will also be based on larger sample of European serial 
innovators in the first and second period, thanks to the availability of additional datasets that will 
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Tables and Figures 
 
Table 1. Number of Serial Innovators and % of Patents by Country and Size, 1990-1995 
Country  N° of Serial Innovators  % of patents per size class and total  Average n° of patent per SI 
  <250  250-500  >500  <250  250-500  >500  total  <250  250-500  >500 
Austria  1  4  32  1.04  2.37  1.12  1.04  16  15  35 
Belgium  -  1  10    4.16  0.84    -  102  83 
Switzerland  7  3  59  4.93  1.55  8.46  4.93  11  13  142 
Germany  38  99  420  22.84  42.55  41.92  22.84  9  11  99 
Denmark  1  5  28  1.88  1.88  1.10  1.88  29  9  39 
Spain  -  3  8    1.55  0.10    -  13  12 
Finland  3  7  22  1.17  6.08  1.57  1.17  6  21  70 
France  7  12  122  5.26  4.21  17.27  5.26  12  9  140 
Great Britain  13  16  133  35.8-11.4  11.43  7.94  35.8-8.9  42-10  18  59 
Ireland  -  1  -    1.02      -  25  - 
Italy  39  31  75  23.04  13.39  5.15  23.04  9  11  64 
Luxembourg  -  -  2      0.09    -  -  46 
Netherlands  4  6  40  3.50  3.92  11.00  3.50  14  16  273 
Norway  -  1  6    0.24  0.32    -  6  54 
Sweden  1  3  32  0.52  5.63  3.11  0.52  8  46  96 
Total  114  192  989  100.00  100.00  100.00  100.00 
     
Source: Our elaborations on D&B (1994) and EPO (1990-1995) data. 
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Table 2. Sector Distribution of Serial Innovators and patents 
Sector Description   Sic2-digit  N° of firms  Average n° of patents per SI 
     <250  250-500   >500  <250  250-500   >500 
Industrial Machinery And Equipment  35  35  54  186  9  11  51 
Electronic & Other Electric Equipment  36  15  16  116  12  11  190 
Chemicals And Allied Products  28  16  19  100  10  13  262 
Fabricated Metal Products  34  7  26  95  8  11  29 
Transportation Equipment  37  3  9  68  11  22  150 
Instruments And Related Products  38  6  18  41  11  11  48 
Primary Metal Industries  33  1  3  37  12  8  66 
Rubber And Misc. Plastics Products  30  9  8  36  9  12  44 
Food And Kindred Products  20  1  2  30  5  45  126 
Stone, Clay, And Glass Products  32  1  5  29  5  7  22 
Business Services  73  6  6  28  81
19  33  56 
Paper And Allied Products  26  -  6  20  -  10  24 
Electric, Gas, And Sanitary Services  49  1  1  17  8  16  68 
Heavy Construction, Ex. Building  16  1  1  16  5  8  94 
Miscellaneous Manufacturing Industries  39  3  3  13  10  7  60 
Furniture And Fixtures  25  1  2  10  7  7  7 
Oil And Gas Extraction  13  -  -  9  -  -  294 
Communication  48  -  -  9  -  -  379 
Lumber And Wood Products  24  2  -  8  6  -  13 
General Building Contractors  15  1  -  7  10  -  33 
Textile Mill Products  22  2  1  6  6  6  13 
Printing And Publishing  27  -  -  4  -  -  48 
Petroleum And Coal Products  29  -  -  4  -  -  108 
Metal Mining  10  -  -  4  -  -  185 
Special Trade Contractors  17  1  1  3  5  15  24 
Apparel And Other Textile Products  23  -  -  3  -  -  45 
Leather And Leather Products  31  1  -  2  6  -  141 
Tobacco Products  21  -  -  2  -  -  33 
U.S. Postal Service  43  -  -  2  -  -  41 
Railroad Transportation  40  -  -  2  -  -  12 
Coal Mining  12  -  -  2  -  -  59 
Transportation Services  47  -  -  1  -  -  19 
Non metallic Minerals, Except Fuels   14  -  -  1  -  -  33 
Trucking And Warehousing  42  1  1  -  17  8  - 
Other sectors*    -  10  78  -  14  49 
Total    114  192  989       
Source: Our elaboration on Epo (1990-1995) and D&B (1993) data. 
(*) Firms have been classified in different sectors according to the primary 2-digit SIC code reported in D&B (1993). D&B reports 
up to five 4-digit SIC codes. Firms with SIC code greater than 49 have been re-classified in the industrial sectors (SIC < 50) 
according to the second SIC code reported in D&B (1993), with the exception of the companies with SIC 73 (Business services) in 
order to observe the companies in the software or research and development sectors, where technology based activities can be 
fundamental. The ones that could not be re-classified according to this criteria (they have just one SIC code in D&B (1993)) has been 
included in the Other sectors category.  
                                                 
19 The high average number of patents per firm is explained by the presence in this sector of BTG that is actually 
classified with SIC 87 in Amadeus (Research, develop., and testing services; 8731: Commercial physical and 
biological research; 8711: Engineering services; 8712: Architectural services). The st. dev. of the average number of 
patents per small-medium firm in this SIC is equal to 170.51. For the other SIC codes, the standard deviation is 




Table 3. Patents by technological classes, 1990-1995 
ISI-INIPI-OST technology classification   No. of Patents  % of patents in each class 
   <250  250-500   >500   <250  250-500   >500 
I.  Electrical engineering             
1 Electrical devices, electrical engineering, electrical energy  164  82  7368  10.8  3.3  7.4 
2 Audio-visual technology  23  7  2826  1.5  0.3  2.8 
3 Telecommunications  50  87  7615  3.3  3.5  7.7 
4 Information technology  30  9  2553  1.9  0.4  2.6 
5 Semiconductors  9  2  1700  0.6  0.1  1.7 
              II. Instruments             
6 Optics  33  15  2931  2.9  0.6  3 
7 Analysis, measurement, control technology  132  122  6359  8.7  5  6.4 
8 Medical technology  109  130  1754  7.2  5.3  1.8 
27 Nuclear engineering  2  17  686  0.1  0.7  0.7 
              III. Chemistry, Pharmaceuticals             
9 Organic fine chemistry  120  138  9862  7.9  5.6  9.9 
10 Macromolecular chemistry, polymers  13  103  5890  0.9  4.2  5.9 
11 Pharmaceuticals, cosmetics  75  75  3352  5  3.1  3.9 
12 Biotechnology  48  39  2021  3.2  1.6  2 
14 Agriculture, food chemistry  23  57  1196  1.5  2.3  1.2 
15 Chemical and petrol industry, basic materials chemistry  21  42  3953  1.4  1.7  4 
              IV. Process engineering             
16 Chemical engineering  45  166  2581  3  6.8  2.6 
17 Surface technology, coating  15  17  1752  1  0.7  1.8 
13 Materials, metallurgy  20  56  3164  1.3  2.3  3.2 
18 Materials processing, textiles, paper  37  174  4652  2.4  7.1  4.7 
24 Handling, printing  77  294  4017  5.1  12  4 
25 Agricultural and food processing, machinery and apparatus 51  67  855  3.4  2.7  0.9 
20 Environmental technology  15  19  1339  1  0.8  1.3 
              V. Mechanical engineering             
21 Machine tools   49  162  1988  3.2  6.6  2 
22 Engines, pumps, turbines  19  35  3040  1.3  1.4  3.1 
19 Thermal processes and apparatus  28  48  1595  1.8  2  1.6 
23 Mechanical Elements  88  102  3588  5.9  4.2  3.6 
26 Transport  55  100  5038  3.6  4.1  5.1 
28 Space technology weapons  -  22  668  -  0.9  0.7 
29 Consumer goods and equipment  77  107  2646  5.1  4.4  2.7 
30 Civil engineering, building, mining  84  155  2095  5.6  6.3  2.1 
Total  1512  2449  99084  100  100  100 
Source: Our elaboration on EPO data (1990-1995)   29  
 
  
Table 4. RTA Index and relative citation intensity by size class, 1990-1995  
ISI-INIPI-OST technology classification  RTA  Relative C/P 
  <250 250-500 >500 <250  250-500  >500 
I.  Electrical engineering             
1 Electrical devices, electrical engineering, electrical energy  0.27  -0.30  0.09  -0.267  -0.086  -0.030 
2 Audio-visual technology  -0.40  -0.85  -0.11 -0.866  0.306  -0.074 
3 Telecommunications  -0.28  -0.24  0.14  -0.167  0.317  -0.058 
4 Information technology  -0.37  -0.84  -0.25  0.044  -1.000  -0.095 
5 Semiconductors  -0.59  -0.93  -0.15  -1  -0.060  -0.061 
              II. Instruments             
6 Optics  -0.34  -0.76  -0.20 -0.469  0.140  -0.013 
7 Analysis, measurement, control technology  0.13  -0.15  -0.02 -0.281  0.004  -0.030 
8 Medical technology  0.24  0.09  -0.43 -0.076  -0.040  0.010 
27 Nuclear engineering  -0.57  0.18  0.18  -1  -0.426  0.007 
              III. Chemistry, Pharmaceuticals             
9 Organic fine chemistry  0.09  -0.08  0.20  -0.320  0.064  0.041 
10 Macromolecular chemistry, polymers  -0.69  -0.05  0.12  -1  0.197  0.004 
11 Pharmaceuticals, cosmetics  0.20  -0.04  0.01  0.045  0.220  0.155 
12 Biotechnology  0.11  -0.23  -0.11 -0.223  -0.076  0.161 
14 Agriculture, food chemistry  0.25  0.43  0.13  -0.259  -0.151  0.144 
15 Chemical and petrol industry, basic materials chemistry  -0.32  -0.23  0.19  0.015  0.065  0.144 
              IV. Process engineering             
16 Chemical engineering  0.02  0.41  -0.05 -0.135  -0.002  0.044 
17 Surface technology, coating  -0.30  -0.46  -0.03 -0.378  0.197  -0.014 
13 Materials, metallurgy  -0.32  -0.05  0.11  -0.344  -0.089  0.062 
18 Materials processing, textiles, paper  -0.28  0.24  0.03  -0.258  -0.141  0.032 
24 Handling, printing  -0.04  0.37  -0.15 -0.068  -0.111  0.028 
25 Agricultural and food processing, machinery and apparatus  0.48  0.39  -0.16 -0.182  -0.045  0.066 
20 Environmental technology  -0.14  -0.26  0.01  -0.218  -0.084  0.015 
              V. Mechanical engineering             
21 Machine tools   0.12  0.44  -0.12  0.164  0.042  0.037 
22 Engines, pumps, turbines  -0.27  -0.21  0.17  -0.200  0.006  -0.037 
19 Thermal processes and apparatus  0.16  0.19  0.09  0.322  -0.249  0.009 
23 Mechanical Elements  0.27  0.11  0.04  0.154  -0.214  0.014 
26 Transport  -0.05  0.01  0.12  0.249  0.077  0.053 
28 Space technology weapons  -1.00  0.29  0.15  -1  -0.204  -0.008 
29 Consumer goods and equipment  0.11  0.03  -0.21  0.009  -0.190  0.093 
30 Civil engineering, building, mining  0.26  0.32  -0.22  0.083  0.030  0.055 
             
Source: Our elaboration on EPO data (1990-1995) 
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Table 5. Small-Medium serial innovators’ strategies of exploitation of their technological innovation 
    Defining events     





trading  Short description  Level of investment in the complementary assets 
Pure 
Strategies             
1. Market for 
technology 
  No  Intermediate  - Licensing 
-R&D/technology 
contracts 
Firms that supply technologies 
disembodied from products. They do not 
enter in the product market and the rents 
from the innovation come from the 
commercialisation of the technologies 
through licensing and or technology 
agreements 
The level of investment in complementary assets is quite low because 
these firms do not have the manufacturing capabilities necessary to enter 




  Yes  Intermediate    Specialised technology-based suppliers that 
develop technologies incorporated in 
components, machines, equipments, 
production processes which are finally 
used by other companies manufacturing 
final or intermediate products 
The level of investment in complementary assets is quite sustained 
because these companies have manufacturing facilities to produce 
components or equipments. The level can then be either ‘high’ for those 
companies investing in the downstream assets for the commercialisation 
of their product, or ‘medium’ in case these companies make 
commercialisation/marketing agreements with other companies.  
3.Market for 
product 
  Yes  Final    Firms that base their activity on the internal 
development and manufacturing of an 
innovative product, whose technology is 
not commercialised to other competitors.  
The level of investment in complementary assets is high because these 
firms have the manufacturing capabilities to produce their final product 
and they also typically make investments in the downstream assets of 
marketing and distribution to compete in the final market 
Mixed 
Strategies             
1 and 2    Yes  Intermediate  - Licensing 
-R&D/technology 
contracts 
These firms are typically very specialised in a technology that they incorporate in the production of a component or 
equipment and that they supply to other firms trough licensing and technology partnerships. In most cases indeed they 
develop broad technologies that can be used into areas not covered by in house manufacturing facilities  





These firms develop technology that they internally incorporate in final products. The level of investment in the 
complementary assets is similar to those highlighted in ‘market for product’ strategy but these firms are able to gain 
returns from innovation also by means of licensing and technology alliances. 
2 and 3    Yes  Intermediate 
and Final 
  These firms are typically specialised in a component or equipment that they both incorporate in a final product 
internally produced and supply to other firms eventually in different product market 
Source: Our elaboration from the first qualitative analysis on small-medium European Serial Innovators’ events (data sources: Asap, Prompt, SDC, company web sites)   31  
 
 
Table 6. ‘Market for technologies’ Strategy 
Country  Company  Description 




Originally spun out from the university in 1992 and now employing 150 people, owns patents 
covering technology relating to light-emitting polymers in display applications. Instead of building 
products itself, CDT has chosen to license to others. 
According to its chief executive David Fyfe, its licensing skills go further still. "We have managed 
to negotiate deals with the likes of Seiko Epson and DuPont which give us the right to sub-license 
their proprietary technology… This allows CDT to act as a one-stop shop for its customers. It is a 
huge advantage … There is nothing that intimidates companies more than having to negotiate 
licensing agreements with many parties… In a sector characterised by multinationals and 
consolidation, CDT's patent portfolio keeps it competitive. … Our business is built on patents. 
They allow us to tiptoe among the elephants… I have no problem getting in to see executives at 
the highest level of very big corporations. For me that is a clear marker for how important we are 
to this sector." (Financial Times, Nov. 13, 2003). 
Several licensing agreements to large companies. Collaboration for external manufacturing of 
displays.  
UK  British 
Technology 
Group 
World leader in the commercialisation of novel technologies. It was born as a private company in 
1992 when a management/employee group led by CIN Venture Managers and including 
institutional investors and universities acquired the state-owned British Technology Group (BTG).  
It has an approach of sharing rewards thus maximising the revenue generated for the sources of 
the technology, for those who bring it to market and for BTG. As a result, it has formed strong 
relationships with many of the world's most innovative research centres as well as major global 
technology companies. Ultimately its success is built on the foundation of the skills of its people, 
who blend science and technology, patent and legal expertise and business know-how. This 
combination of skills allows BTG to effectively capture value from its technologies through 
licensing the rights or by developing new business ventures (http://www.btgplc.com).  




CAT was established in 1990 and listed on the London Stock Exchange in 1997. It currently 
employs around 270 people. The Company's success is based on the application of this platform 
technology for the rapid isolation of monoclonal antibodies. CAT has two strands to its business: 
developing proprietary products and licensing its technologies and capabilities to enable others to 
develop products – thereby balancing risk and reward. To maximise commercial opportunities, 
CAT has indeed built an array of strategic collaborations with leading pharmaceutical and 
biotechnology companies worldwide. Its strategy is to exploit the power of its platform technology 
to build a balance of long-term revenues from the development of novel antibody-based 
therapeutic products, and short-term revenues from research collaborations and licences of its 
technology. CAT's patent portfolio includes about 30 families of patents, covering both 
technologies and products. 
FI  Biotie Therapies  Drug development company with a focus on dependence disorders, inflammatory diseases and 
glycobiology. The company has an extensive product portfolio with products in all phases of 
clinical development. BioTie’s focuses on projects of preclinical and early clinical research. 
Collaboration and licensing agreements with global pharmaceutical companies provides the 
necessary financial and complementary resources for late stage clinical development and 
marketing. According to BioTie’s strategy the products will be licensed at an optimal stage of 
project development, taking the available financial assets of the company into account. The 
company aims at entering into large-scale, comprehensive (covering North America and Europe in 
particular) development and marketing agreements with international pharmaceutical companies. 
DK  Neurosearch  NeuroSearch is a Biopharmaceutical company focused on unmet medical needs within diseases in 
the Central Nervous System and other diseases treated primarily through ion channel modulation. 
NeuroSearch has a broad research and development portfolio which includes compounds 
compounds in clinical development and a number of pre-clinical and drug discovery programs. 
NeuroSearch signed several development and licensing agreements with companies like 
Boehringer Ingelheim GlaxoSmithKline, Pharmexa and Pierre Fabre.  
Source: Our elaborations on ASAP, Promt and SDC databases and Internet web sites   32  
 
Table 7. ‘Market for embedded technologies’ Strategy  
Country Company  Description 
DE  ALTEN 
GERÄTEBAU 
GMBH 
Alten Geratebau develops, manufactures and commercialises dock levellers, dock shelters and 
industrial doors to promote the efficiency of materials handling in the loading bay. Acquired in 
1998 by the Swedish Cardo Group to become the market leader in Europe in dock loading 
technologies and equipment.  
DE  Sihi Gmbh  Founded on the innovative ideas of engineers petrols Siemen and Johannes Hinsch in the areas of 
sucking in hydraulic pumps and liquid-along-promoting vaccum pumps. It produces vacuum pumps 
and systems for several types of vehicles. In 1997 acquired by Sterling Fluid Holdings of the 
Thyssen Bornemisza group. 
IT  M.G. BRAIBANTI 
S.p.A. 
Historical leader in pasta processing technology. The continuous press is the machine that really 
got the industrialization of pasta under way. Invented by the Frenchman Sandragné in 1917 and 
finally perfected by the brothers Mario and Giuseppe Braibanti in 1933, this machine is traditionally 
considered by pasta makers to be the "heart" of every pasta production line. Braibanti equipment 
is installed in many factories. 
IT  PRIMA 
INDUSTRIE S.p.A. 
Established in 1977 to operate in the field of engineering and R&D, during the 80s the company 
develops a number of winning high-tech products in the fields of laser robotics, measuring robotics 
and welding robotics. At the beginning of the 90s the company gradually starts to focus its activity 
in the specific field of laser machines. Designs, manufactures, sells and services high power laser 
machines and lasers for the cutting, welding and drilling of 3D and 2D parts. In 2001 the company 
acquires Laserdyne and Convergent Energy with manufacturing facilities. 
IT  NUOVA ROJ 
ELECTROTEX 
S.R.L. 
Nuova Roj Electrotex is a technological partner for builders of textile machinery. Develops projects 
of industrial automation according to the customer's request. Internal R&D, manufacturing and 
sales. Acquired in 1992 by IRO Group. 
UK  THOMAS 
BROADBENT &  
SONS LIMITED 
Thomas Broadbent designs and manufactures advanced technology separation (centrifuge) 
systems. Its customer base is drawn from processing industries such as chemicals, oil, gas, food, 
pharmaceuticals, sugar cane and beet, minerals, plus environmental protection applications 
including flue gas desulphurisation and sludge dewatering, whilst a third of turnover is in the 
domain of commercial laundry equipment. 
SE  ALLGON AB  Allgon produces antenna systems for infrastructure in mobile telephone networks; filters, 
combiners and similar products for base stations; repeater networks and microwave equipment. 
Many supply agreements with large telecommunication companies. Rapid growth of turnover and 
employees. In 1997 among the Best Small Firms in the Forbes list. Acquired by LGP Telecom in 
2003. Providers of engineering, planning and deployment service, support of client telecom 
networks, maintenance and repair of critical network elements including antennas and base station 
equipment, training for client's internal network operations and support staff. 
Source: Our elaborations on ASAP, Promt and SDC databases and Internet web sites 
 
Table 8. ‘Market for products’ Strategy  
Country Company  Description 
IT  CIMBALI S.p.A.  Producer of Cappuccino Machines, Coffee Equipment Faucets, Coffee Makers, Espresso Machines, 
Glass Washers, Ice Makers & Dispensers. R&D oriented: 40 engineers in the R&D department and 
several patents. Investments in downstream complementary assets of training and assistance, 
international distribution network. 
IT  DURST 
PHOTOTECHNIK 
A.G. 
Manufacturer of digital products for the photographic, graphic and prepress markets. Development 
of technologies for digital print. Several patents and introduction of innovative products, Joint 
agreements for product development, mass production, foreign subsidiaries with manufacturing 
facilities.  
IT  MELICONI S.p.A.  Established in the late 60s. Operates in the houseware market, producing household and kitchen 
accessories in plastic and metal, Video Hi-Fi accessories. In 1987 introduces the BODYGUARD, a 
shockproof protection for remote controls, based on the development of innovative materials. 
Introduction of other household and kitchen accessories with the same materials. Downstream 
investments in distribution and advertising.  
CH  DISETRONIC 
MEDICAL 
SYSTEMS 
Company specialized in pharmaceutical delivery systems. The company makes medical infusion 
pumps regulated by microprocessors and self-injection pens for diabetics and others who need 
frequent injections. To succeed against competition, the founders decided not to market their 
pumps alone but rather to team up with pharmaceutical companies and leave distribution to them. 
This entailed enormous cost savings.  
Disetronic Supplies leading health-care companies and genetic engineering boutiques like the 
Roche group, Hoechst, Eli Lilly and Genentech. 
UK  ELONEX PLC  Manufacturing and sales of PCs. Development of technologies incorporated in the PCs but also 
sold through licensing agreements. 




Table 9. Mixed strategies  
Country  Type of Mixed 
Strategy 
Company  Description 
IT  MfET and MfP  ASKOLL S.p.A.  In 1978 Elio Marioni invents the synchronous pump for aquariums, simpler 
and more reliable than the traditional asynchronous pump. Askoll technology 
is widely adopted (50 million aquariums use its technology). In 1986 the 
synchronous technology developed by Askoll is applied to home appliances 
like washing machines and dishwashers (80 million dishwashers produced by 
large companies adopt the Askoll Inside concept).  In 2000 the synchronous 
pump is applied to the heating systems. Askoll also produces aquariums and 
other products for gardening embodying the synchronous pump.  
DE  MfET and MfT  Zipperling Kessler 
&  Co  
Zipperling Kessler is a pioneer in development of conductive polymers, 
including polyaniline. With its 100% subsidiary Ormecon (founded in 1996), 
Zipperling has now a research history in conductive polymers and Organic 
Metals of more than 20 years. They perform basic and applied research 
devoted to chemistry, physics, dispersion, processing and applications of 
conductive polymers, especially their proprietary organic metal polyaniline 
(polyphenylene amine). Ormecon is the first and only company in the world to 
supply the Organic Metal. The technology is based on research and 
development done at Zipperling Kessler and covered by more than 200 
patents owned by Zipperling Kessler. In 2003, five additional institutional 
investors have joined the company as shareholders. Besides commercial 
products, Ormecon International offers R&D service and grants licenses 
around the Organic Metal (ORMECON
TM) for technology partnerships. Such 
partnerships are already established with BAYER, DuPont, Panipol, COVION, 
Avecia and Nissan Chemical Industries. Ormecon International continues 
fundamental and applied research. With a world-wide customer base of over 
120 customers and approx. 25 sales partners, Ormecon International is now 
market leading in the field of Immersion Tin.
20  
IT  MfP and MfT  ROTTA RESEARCH 
LABORATORIUM 
S.P.A. 
Rotta Research Laboratorium was founded in 1961 (by a pharmacology 
professor of the University of Pavia,) as an independent research laboratory 
that gave rise to the Rottapharm group. It is a multinational pharmaceutical 
group engaged in the production and trade in chemicals, medicines, 
pharmaceuticals and diagnostic products. To date the intense research activity 
has generated 2,729 new molecules, 287 patents and 19 compounds, which 
are at an advanced stage of research. Nine original products are sold 
worldwide. It has acquired companies with research, manufacturing or sales 
facilities and has later established sales and marketing subsidiaries in Europe 
and outside Europe. It has been involved in several licensing agreements. An 
example: Sanofi SA, a unit of Societe Nationale Elf Aquitaine, a subsidiary   of 
France's state-owned ERAP, formed a strategic alliance with Rotta Research 
Spa to develop, license and market osteoporosis and anti-menapause 
therapeutic drugs. Under the terms of the agreement, the alliance was to 
include licensing, distribution agreements or joint ventures in more than 50 
countries. The alliance involved six products of Rotta Research which included 
Dermestril estrogen path, Dona glucosamine sulfate, Tridine 
monofluorophosphate and the Afloxan anti-inflammatory drug. In exchange, in 
the medium-term Rotta was to receive non-exclusive marketing rights to 
certain Sanofi products. In the long-term, Sanofi was to support Rotta's 
expansion into areas in which it did not have facilities. 





                                                 
20 http://www2.ormecon.de/News/ZF004.en.html.    34  
 
 
Figure 1. Small-Medium serial innovators (1990-1995) by Type of Strategy  
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Source: Our classification of the sample of 114 small-medium European Serial innovators (1990-1995) according to 
the taxonomy described in Table 5 
 
Table 10. Small-medium serial innovators (1990-1995) by type of Strategies and Country 






NA  Total 
                 
Austria        1        1 
Switzerland    4  3          7 
Germany    18  14  1  3    2  38 
Denmark  1              1 
Finland  1  1  1          3 
France    2  2  1  2      7 
Great Britain  3  6  4          13 
Italy    15  19    1  4    39 
Netherlands    1  2  1        4 
sweden    1            1 
                 
Total  5  48  45  4  6  4  2  114 
Source: Our classification of the sample of 114 small-medium European Serial innovators (1990-1995)   35  
 
 
Table 11. Small-Medium Serial Innovators by type of Strategies and Sector of activity 
  SIC 






T-P  NA Total 
General Building Contractors  15      1          1 
Heavy Construction, Ex. Building  16    1            1 
Special Trade Contractors  17      1          1 
Food And Kindred Products  20    1            1 
Textile Mill Products  22    1  1          2 
Lumber And Wood Products  24    1  1          2 
Furniture And Fixtures  25      1          1 
Chemicals And Allied Products  28  2  1  5  1  1  5    15 
Rubber And Misc. Plastics Products  30    3  3  1  1    1  9 
Leather And Leather Products  31      1          1 
Stone, Clay, And Glass Products  32      1          1 
Primary Metal Industries  33    1            1 
Fabricated Metal Products  34    3  3    1      7 
Industrial Machinery And Equipment  35    21  10  2  2      35 
Electronic & Other Electric Equipment  36    7  6    1    1  15 
Transportation Equipment  37    2  1          3 
Instruments And Related Products  38    1  5          6 
Miscellaneous Manufacturing Industries  39    2  1          3 
Trucking And Warehousing  42      1          1 
Electric, Gas, And Sanitary Services  49    1            1 
Business Services  73  1  2  3          5 
Engineering Services  87  2              2 
 
Total  5  48  45  4  6  5  2  114 
Source: Our classification of the sample of 114 small-medium European Serial innovators (1990-1995) 




Table 12. Small-Medium Serial Innovators characteristics by type of Strategy 






             
Freq.   5  48  45  6  4  4 
             



























             
SIC concentration
(*)  0.52  0.229  0.110  0.222  0.375  1 
             
Average number of patents per firm 












             
Technological diversification 




0.36 – 0.447 











             
Number of citations  354-112  548  367  67  100  47 
Citation intensity (C/P)   0.73- 2.07  1.03  0.98  1.52  1.56  1.47 
Citations / firm  70.80-22.40  11.42  8.16  16.75  16.67  11.75 
 % of cited patents  0.19-0.16  0.24  0.25  0.22  0.20  0.26 
             
Source: Our elaborations on the sample of 114 small-medium European Serial innovators (1990-1995) 
(*) Herfindhal index calculated on 2 digit SIC  
(**) Herfindhal index calculated on patent technological classes (ISI – INIPI – OST classification) at  
the firm level by type of strategy. 
 
 
 
 